Radio Advisory

Employer-sponsored insurance is reaching a tipping point. What was once a predictable 2–4% annual increase in employer health spending has given way to double digit growth, driven by surging drug costs, rising utilization across all age groups, and escalating provider rates. For many employers—especially smaller organizations with less margin for error—absorbing these costs is no longer viable. As economic conditions shift and the labor market cools, the balance of power between employers and employees is changing, opening the door to more aggressive cost-control strategies. In this episode, host Rachel (Rae) Woods is joined by Advisory Board expert Sally Kim to unpack what’s behind the spike in employer health costs—and what employers are doing about it. They walk through the full “menu” of options now on the table, from benefit redesign and navigation tools to network strategy, direct contracting, and alternative funding models. The conversation explores what these moves mean for health plans and providers competing for commercial lives—and why understanding employer behavior is no longer optional. We’re here to help: Ready-to-Use Slides | Market outlook for employer-sponsored insurance Listen | Ep. 232: The rise of ICHRAs: Why some employers are turning to the individual market Listen | Ep. 286: A Medicare Advantage reset — and what comes next Expert Insight | How employers are combating the ‘new normal’ for benefits costs with unconventional measures How UT Southwestern closed genomic testing gaps in prostate cancer care A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

For life sciences companies, access and adoption of clinical products is no longer as simple as demonstrating strong outcomes at a fair price. As payers and providers face mounting financial pressure and operational complexity, they are scrutinizing their partners more closely — expecting clearer evidence, more relevant value narratives, and support that reflects real world constraints. In this episode, host Rachel (Rae) Woods sits down with Advisory Board experts Gina Lohr and Nick Hula to unpack how med tech and pharma companies should adapt their product and partnership strategies. Together, they explore why a single value story no longer works — and how life sciences organizations can better align their products, evidence, and engagement strategies to meet the rising expectations of payers, health systems, ambulatory leaders, clinicians, and patients. We’re here to help: Expert insight | The top 5 trends impacting med tech strategies in 2026 Expert insight | 5 trends shaping pharma strategy for 2026 (and how to adapt) Podcast | Ep. 242: How you should rethink your life sciences-health system partnerships How Highlands Oncology expanded access to oral oncolytics treatment A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

As health systems pursue growth beyond traditional avenues, the role of the strategic planner is becoming increasingly complex. High level directional data is no longer enough — achieving meaningful, differentiated growth now requires leveraging granular, sophisticated data to inform investment decisions. In this episode, host Rachel Woods sits down with Advisory Board experts Sebastian Beckman and Ellie Wiles to explore how health systems can rethink strategic planning for 2026 and beyond. Together, they unpack what it should actually look like to democratize data, why data governance matters just as much as data access, and how service line leaders can partner with planners to make faster, more precise, margin savvy decisions. We’re here to help: Podcast | 289: What are health systems doing in 2026? Results from our survey are in. Playlist | Radio Advisory Provider Strategy and Financial Outlook Playlist Case Study | How UT Southwestern closed genomic testing gaps in prostate cancer care ICYMI: Webinar | The top 10 trends impacting health systems in 2026 Tools | Check out Advisory Board’s Market Scenario Planner and other Advisory Board analytics and data tools to inform your strategy for growth, cost control and more. Comprehensive women’s healthcare: Redefining the standard of care A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

Alex Kist, an Optum consultant on health system operations and growth, and Marisa Nives, an Advisory Board researcher who leads the Strategic Planner Survey, discuss 2025 performance and 2026 priorities. They unpack why revenue gains often fail to become margin, the role of operational excellence, throughput and referral capture, ambulatory and primary care growth, and where systems should focus resources and tech investment.

Chloe Bakst, pharmacy policy pro focused on 340B program dynamics and drug pricing. Nick Hula, payment policy analyst who tracks site-neutral payments and inpatient-list shifts. Claire Wirth, value-based care strategist decoding new CMMI models. They discuss the surge in value-based payment models, site-of-care and payment alignment changes, and the chaotic, rapidly evolving 340B policy landscape.

Infusion services make up a roughly $150 billion market in the U.S., and underpin the financial stability of major service lines, especially oncology. Historically, health systems have enjoyed strong volumes, favorable reimbursement, and access to 340B discounts that keep their infusion business profitable. But rising competition, payer and employer driven site of care shifts, and looming policy changes are putting pressure on what many leaders have relied on as a stable, margin accretive business. In this episode, host Abby Burns sits down with Advisory Board expert Chloe Bakst to break down what’s actually happening in the infusion market — and why every health system leader should be paying closer attention. Together, they explore how new competitors are capturing leakage you may not even see, how payers and employers are steering patients away from hospital outpatient departments, and how upcoming 340B reforms and Medicare drug price negotiations could reshape the economics of infusion over the next three years. Chloe also shares the strategies forward thinking systems are using to protect their infusion business and prepare for rapidly emerging headwinds. We’re here to help: Webinar | The top trends in today’s infusion market Tool | Market Scenario Planner Ready-to-Use Resource | Policy Scenario Impact Calculator Expert Insight | The 3 trends reshaping the specialty drug pipeline today Podcast | 270: Service line snapshot: What every health leader needs to know Webinar | Join Optum Advisory experts at this upcoming webinar to learn how optimizing patient access unlocks the value of digital innovations and drives long-term sustainability. Expert Insight | How data-driven risk reduction protects patients and providers A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

Once a high growth, high margin line of business for health plans, Medicare Advantage (MA) is now in the middle of a financial reset. Growth has slowed, margins have turned negative, and federal financial support is eroding — with CMS proposing a near flat reimbursement increase for 2027. As a result, plans are exiting markets, tightening benefit designs, and shifting their focus toward Special Needs Plans (SNPs). At the same time, seniors are facing rising costs, fewer perks, and more frequent plan changes. To cut through the noise and understand what’s really happening beneath the headlines, host Rachel (Rae) Woods speaks with Advisory Board experts Sally Kim and Aaron Hill about the new divide emerging in MA: between plans equipped to manage the intensive needs of high cost seniors and execute on SNP strategies — and those that will be forced to exit markets or rethink their MA ambitions entirely. Listen as they break down how MA’s financial and clinical headwinds are reshaping payer–provider relationships — and why future success depends on disciplined focus, deeper provider partnerships, and new investments in technology and cross benefit management. We’re here to help: Tool | Medicare Market Explorer Webinar | Medicare Advantage: Insights on today’s more competitive market Webinar | Medicare Advantage: The latest on product design and growth Podcast | Ep. 227: The changing tide of Medicare Advantage Expert Insight | 3 data-driven insights on Medicare Advantage Star Ratings Ready-to-Use Slides | Medicare Advantage market outlook 2026 Advisory Board Summit Washington, D.C. A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

As financial pressure mounts and the healthcare safety net continues to strain, academic medical centers are drawing on their culture of innovation to pursue better outcomes — and narrow life expectancy gaps in the communities they serve. In this episode of Radio Advisory, host Rae Woods sits down with leaders from Rush University Medical Center to explore how health systems can stay focused on results amid tightening margins, political scrutiny, and ongoing uncertainty in grant funding. Dr. Omar Lateef, President and CEO of Rush, and Dr. David Ansell, Senior Vice President for Community Health Equity, describe how Rush treats gap-reduction as a long-term operating strategy rather than a moral or messaging exercise. They share practical examples of how local partnerships, targeted investments, and day-to-day operational choices can improve outcomes while still making financial sense — and why avoiding battles over language helps keep the focus squarely on results. We’re here to help: How Rush University Medical Center is addressing the root causes of social determinants of health 264: Research funding is being slashed. What’s the real industry impact? How research funding cuts are impacting healthcare (and how to respond) 12 things CEOs need to know in 2026 Healthcare Policy Updates Timeline Tool: How policy changes will impact your bottom line Who gets the chance to be healthy? | Rush The Rush Center for Community Well-Being at Sankofa Wellness Village | Rush Health disparities in Chicago and the work to solve them with Rush University Medical Center (AMA) The Anchor Strategy — A Place-Based Business Approach for Health Equity | New England Journal of Medicine Rush Signs on as First Partner for Local Laundry Service | Rush David Ansell Books – New: The Death Gap 2026 Advisory Board Summit Washington, D.C. A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

Pediatric hospitals are one of the most important segments in the industry to watch right now. Although children’s hospitals make up only 5% of total hospital market share, more than 40% of U.S. children rely on Medicaid, leaving pediatric organizations disproportionately exposed as the Medicaid-related provisions of the One Big Beautiful Bill Act take effect. The pressures inside pediatric care were mounting even before this moment. After years of outperforming adult hospitals, children’s hospitals have seen margins fall from double digits to just 1% last year. Rising bad debt, higher supply and labor costs, a rapid shift toward lower margin outpatient care, and emerging challenges like declining birth rates and vaccine policy upheaval have created a perfect financial storm. While some of these dynamics are unique to pediatrics, the sector also offers an early warning signal for the rest of healthcare — and an opportunity to translate lessons across both worlds. In this episode, host Abby Burns and Advisory Board expert Vidal Seegobin break down why pediatric leaders must simultaneously manage immediate-term margin pressure, prepare for a more ambulatory-dominant model, and futureproof their organizations amid shifting demographics. Vidal also shares actionable steps leaders can take now, along with the critical lessons pediatric hospitals offer the wider healthcare ecosystem. We’re here to help: 5 insights on the state of pediatric hospitals today 12 things CEOs need to know in 2026 The State of the Healthcare Industry in 2026 Read Advisory Board's 2026 research agenda 3 trends shaping healthcare in 2026 (and how to respond) 278: Dr. Emily Oster on fighting misinformation and rebuilding trust in healthcare 277: Patient distrust is costing you. Here’s how to rebuild it. Learn how outpatient shifts can impact your organization by using Advisory Board’s Market Scenario Planner tool. Sign up today for this Optum Health Webinar: Scaling your EHR: How Optum Health built an enterprise platform to redefine care delivery. A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

Spencer Nadolsky, MD, obesity and lipid specialist who builds direct-care models; Angela Fitch, MD, internal/pediatric physician focused on patient-centered metabolic homes; Florencia Halperin, MD, endocrinologist leading telehealth obesity care. They tackle GLP-1 hype, access and cost challenges. They debate medication-only approaches versus wraparound care. They explore payer strategies and what true, sustainable obesity care will require.